Growing evidence supports its clinical relevance across malignancies: microRNA-486-3p-mediated regulation of TMIGD2 influences cisplatin resistance in ovarian cancer (77), while miR-615-5p exerts antitumor effects in cervical cancer via TMIGD2 targeting (78). Here, TMIGD2 is linked to ovarian carcinoma.